

Clinical Oversight Review Board (CORB) Criteria for Prescribing/ Criteria-Based Consultation (CBC) Criteria for Coverage

Risdiplam (Evrysdi)

Notes:

- Quantity Limits: Yes
- * Tracheostomy: surgically created hole in front of neck for placement of a tube into windpipe to help with breathing
- ^ Noninvasive ventilation refers to positive pressure ventilation delivered through a noninvasive interface (nasal mask, facemask, or nasal plugs)

Non-Formulary **risdiplam (Evrysdi)** requires a clinical review. Appropriateness of therapy will be based on the following criteria:

Initiation (new start) criteria, criteria for current Kaiser Permanente members already taking the medication who have not been reviewed previously, and criteria for new members entering Kaiser Permanente already taking the medication who have not been reviewed previously: Non-formulary **risdiplam (Evrysdi)** will be covered on the prescription drug benefit for 12 months when the following criteria are met:

- Prescribed by a neurologist with specialty in neuromuscular disorders
- Patient's age is 2 months to 25 years old at treatment initiation
- Patient has a confirmed diagnosis of 5q-autosomal recessive spinal muscular atrophy (SMA) with biallelic deletions or mutations in the SMN1 gene
- Patient has 2 to 4 copies of the SMN2 gene
- Patient is not using other treatments for SMA
- Patient has not had prior treatment and is not planning treatment with onasemnogene abeparvovec (Zolgensma) or other gene therapy for SMA
- Patient does not require permanent invasive ventilation or tracheostomy*
- Patient is not dependent on invasive or noninvasive ventilation^ support during waking hours each day
- Patient has been reviewed by the Kaiser Permanente Interregional Consultative Physician Panel, with recommendation to use medication

Continued use criteria for patients previously approved per the above criteria who are currently stable on the medication: Non-formulary **risdiplam (Evrysdi)** will continue to be covered on the prescription drug benefit for 12 months when the following criteria are met:

- Continues to be prescribed by a neurologist with specialty in neuromuscular disorders

kp.org

Revised: 04/13/23
Effective: 06/08/23

All plans offered and underwritten by
Kaiser Foundation Health Plan of the Northwest

Clinical Oversight Review Board (CORB) Criteria for Prescribing/
Criteria-Based Consultation (CBC) Criteria for Coverage

Risdiplam (Evrysdi)

- Patient is not using other treatments for SMA
- Patient has not had prior treatment and is not planning treatment with onasemnogene abeparvovec (Zolgensma) or other gene therapy for SMA
- Patient does not require permanent invasive ventilation or tracheostomy*
- Patient is not dependent on invasive or noninvasive ventilation^ support during waking hours each day
- Patient has not experienced loss of function or progressive weakness (physical and/or pulmonary)

kp.org

Revised: 04/13/23
Effective: 06/08/23

All plans offered and underwritten by
Kaiser Foundation Health Plan of the Northwest